Leadership

Maxwell Stock
President & CEO

Has the primary responsibility of spearheading Signum’s business development efforts in combination with developing strategic plans to advance the company’s mission and objectives. An inventor on Signum patents and a co-founder of the company, his extensive laboratory experience and familiarity with our science have been critical in executing and maintaining Signum’s strategic partnerships.  He majored in molecular biology at the University of Colorado, conducted research efforts at Synergen, Inc., and founded several startups before founding Signum and joining Professor Stock’s Princeton laboratory to develop the technologies upon which Signum is built.

Jane M. Maida
Chief Financial Officer

Jane brings more than twenty years of healthcare industry financial experience to Signum. Most recently, she served as CFO Officer of Abeille Pharmaceuticals, a biotechnology company focused on improving a drug's administration and thereby decreasing side effects; CFO and Chief Accounting Officer at  Physiome Sciences (sold to Predix Pharmaceuticals), a biotechnology company focusing on the software development for modeling of various cells, tissues and organs. Prior to that, she was Vice President of Finance and Chief Accounting Officer of Cytogen Corporation (now part of EUSA Pharma), an oncology focused biotechnology company. Other positions include Chief Financial and Information Officer at Mustard Seed, a behavioral healthcare company and Director of Finance at The Liposome Company (now part of Elan), a biotechnology company.

Eduardo Perez, PhD
Vice President of R&D and Business Development
Leads our business development efforts in combination with supporting pharmaceutical and nutraceutical development. Since joining Signum in 2006, Eddie has been a key contributor in securing funding for the company via executing out-licensing deals and government funding. Prior, to joining Signum, he received his PhD in Biochemistry and Molecular Biology from UMDNJ studying the role of methylation in signaling systems. He received his BA in Biology from Rutgers University.

Michael Voronkov, PhD
Vice President of Medicinal Chemistry

Leads our small molecule and preclinical development effort at Signum Biosciences.  Before coming to Signum, he led R&D effort at MosChemPharm (Russia) and prior to that worked in Drug Discovery at Lexicon Pharmaceuticals. He received his PhD in Organic Chemistry from Emory University and his BA in Chemical Engineering from St. Petersburg Institute of Chemical Technology (Russia).